Triple therapy in uncontrolled asthma: a network meta-analysis of phase III studies Source: Eur Respir J, 58 (3) 2004233; 10.1183/13993003.04233-2020 Year: 2021
Phase III trial of tiotropium as add-on therapy to low-dose inhaled corticosteroids for patients with symptomatic mild persistent asthma: Design and planned analyses Source: Annual Congress 2013 –Asthma drugs: new findings Year: 2013
Who should receive which biologic and why? Current and future approaches in severe asthma patients Source: Virtual Congress 2021 – Linking scientific mechanisms to recent clinical therapeutic advances in airway disease: why, who, when and what? Year: 2021
Late Breaking Abstract - Can a self-management plan, which includes a four-fold increase in inhaled corticosteroid dose, reduce severe asthma exacerbations: a randomised, pragmatic trial. Source: International Congress 2017 – Late-breaking findings in asthma and COPD Year: 2017
Late Breaking Abstract - Long-term safety and efficacy of benralizumab in severe, uncontrolled asthma: first results of BORA, a randomized, Phase III extension study Source: International Congress 2018 – Notable Studies in Asthma Year: 2018
Latent classes of adults with persistent asthma: data from the multicentre INSPIRERS studies Source: Virtual Congress 2020 – Management of allergy, asthma and COPD Year: 2020
Less is more: the impact of maintenance treatment adherence in severe asthma clinical trials Source: Eur Respir J, 53 (5) 1900599; 10.1183/13993003.00599-2019 Year: 2019
Using placebo-controlled trials to define predictors of future exacerbations in severe asthma patients Source: Eur Respir J, 58 (6) 2101702; 10.1183/13993003.01702-2021 Year: 2021
Roflumilast for stable COPD: Meta-analysis of randomized controlled trials Source: International Congress 2014 – Clinical presentations Year: 2014
Influence of patient baseline characteristics and concomitant medication on outcomes in long-term trials of COPD: Analysis of the UPLIFT® trial Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD Year: 2013
How to define asthma in large-scale studies? Source: International Congress 2014 – Is asthma prevalence still increasing? Year: 2014
Real-life study on the aPpropriaTeness of treatment in moderate COPD patients (OPTIMO) Source: Annual Congress 2013 –COPD drugs: new findings Year: 2013
Omalizumab reduces asthma exacerbations and oral corticosteroid use in patients with severe allergic asthma: a systematic review of observational studies Source: International Congress 2019 – Clinical studies of asthma treatments Year: 2019
Can we predict response of refractory asthmatic cough to tiotropium? :a prospective study Source: Virtual Congress 2020 – Chronic cough: only symptom or disease? Year: 2020
Omalizumab in children with severe asthma (SA): Which parameters improve after a 16 week trial? Source: Annual Congress 2010 - Managing asthma and allergic disease in children Year: 2010
Maintenance and reliever combination budesonide/formoterol therapy in asthma patients at risk of severe exacerbations: A randomised controlled trial Source: Annual Congress 2013 –LAMA, LABA, ICS and their combinations for the treatment of asthma and COPD Year: 2013
Clinical phenotypes of asthmatics who require long-term use of tiotropium for asthma control: a real-world study Source: International Congress 2019 – Clinical studies of asthma treatments Year: 2019